scholarly journals Long-Term Performance of Vagus Nerve Stimulation Lead: Low Rate of Complications and Failures

2019 ◽  
Vol 25 (8) ◽  
pp. S177-S178
Author(s):  
Imad Libbus ◽  
Scott R. Stubbs ◽  
Scott Mindrebo ◽  
Bruce H. KenKnight ◽  
Lorenzo A. DiCarlo
2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
I Libbus ◽  
S Stubbs ◽  
S Mindrebo ◽  
B Kenknight ◽  
L Dicarlo

Abstract Background Autonomic Regulation Therapy (ART) is a novel therapy for heart failure (HF) that has been shown in a pilot study to be associated with improvement in left ventricular function, 6-minute walk distance, NYHA class, and quality of life. ART is provided using chronic stimulation through a self-sizing lead that is placed on the cervical vagus nerve without any need for response-mapping. The lead is functionally identical in its design and manufacture to a commercially available lead that has been implanted since February 2009 for the treatment of refractory epilepsy and treatment-resistant depression. Purpose A survival analysis was performed to evaluate long-term lead performance. Methods Lead survival was calculated for those patients whose survival status was obtainable from public records. All devices registered as implanted in the United States for any indication were included for the analysis. All available data on device explants, device replacements, returned product analyses, and customer complaints were collected and used to identify failures and out-of-specification conditions. Device survival probability was defined as the likelihood of the implanted device remaining implanted and performing as intended. Results As of the time of this analysis, there have been 26467 registered system implantations and a total of 53200 device-years of lead use. Survival status was obtainable for 9700 patients from public records. After 1 year, 99.5% of implanted leads have remained implanted and performing as intended. At 7 years, 95.8% of leads have remained implanted and performing as intended. The most common causes of lead failure have been infection (0.87%), vocal cord dysfunction (0.68%), lead protrusion (0.36%), and lead extrusion (0.27%). At implant 1 year 2 year 3 year 5 year 7 year Cumulative Survival Probability (%) 100 99.5 (99.4–99.6) 99.1 (98.8–99.2) 98.6 (98.4–98.9) 97.4 (96.9–97.7) 95.8 (94.9–96.5) Number of Patients 9700 8500 7200 6000 3300 700 Conclusions Lead performance during chronic vagus nerve stimulation has included over 5ehz746.0379 device-years of use in over 25000 patients. A low rate of long term complications and failures have been reported, and the cumulative survival probability of the lead appears to be high. Acknowledgement/Funding LivaNova PLC


2020 ◽  
Vol 7 (1) ◽  
pp. 26-29
Author(s):  
Inder Anand ◽  
Imad Libbus ◽  
Lorenzo DiCarlo

2014 ◽  
Vol 7 (6) ◽  
pp. 914-916 ◽  
Author(s):  
Didier Clarençon ◽  
Sonia Pellissier ◽  
Valérie Sinniger ◽  
Astrid Kibleur ◽  
Dominique Hoffman ◽  
...  

2019 ◽  
Vol 20 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Laura Pérez-Carbonell ◽  
Howard Faulkner ◽  
Sean Higgins ◽  
Michalis Koutroumanidis ◽  
Guy Leschziner

Vagus nerve stimulation (VNS) is a neuromodulatory therapeutic option for drug-resistant epilepsy. In randomised controlled trials, VNS implantation has resulted in over 50% reduction in seizure frequency in 26%–40% of patients within 1 year. Long-term uncontrolled studies suggest better responses to VNS over time; however, the assessment of other potential predictive factors has led to contradictory results. Although initially designed for managing focal seizures, its use has been extended to other forms of drug-resistant epilepsy. In this review, we discuss the evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy. We also include practical guidance for the approach to and the management of patients with VNS in situ.


2016 ◽  
Vol 32 (4) ◽  
pp. 641-646 ◽  
Author(s):  
Ayse Serdaroglu ◽  
Ebru Arhan ◽  
Gökhan Kurt ◽  
Atilla Erdem ◽  
Tugba Hirfanoglu ◽  
...  

2020 ◽  
Vol 34 (7) ◽  
pp. 609-615
Author(s):  
Jesse Dawson ◽  
Navzer D. Engineer ◽  
Cecília N. Prudente ◽  
David Pierce ◽  
Gerard Francisco ◽  
...  

Background. Vagus nerve stimulation (VNS) paired with rehabilitation may improve upper-limb impairment and function after ischemic stroke. Objective. To report 1-year safety, feasibility, adherence, and outcome data from a home exercise program paired with VNS using long-term follow-up data from a randomized double-blind study of rehabilitation therapy paired with Active VNS (n = 8) or Control VNS (n = 9). Methods. All people were implanted with a VNS device and underwent 6 weeks in clinic therapy with Control or Active VNS followed by home exercises through day 90. Thereafter, participants and investigators were unblinded. The Control VNS group then received 6 weeks in-clinic Active VNS (Cross-VNS group). All participants then performed an individualized home exercise program with self-administered Active VNS. Data from this phase are reported here. Outcome measures were Fugl-Meyer Assessment—Upper Extremity (FMA-UE), Wolf Motor Function Test (Functional and Time), Box and Block Test, Nine-Hole Peg Test, Stroke Impact Scale, and Motor Activity Log. Results. There were no VNS treatment–related serious adverse events during the long-term therapy. Two participants discontinued prior to receiving the full crossover VNS. On average, participants performed 200 ± 63 home therapy sessions, representing device use on 57.4% of home exercise days available for each participant. Pooled analysis revealed that 1 year after randomization, the FMA-UE score increased by 9.2 points (95% CI = 4.7 to 13.7; P = .001; n = 15). Other functional measures were also improved at 1 year. Conclusions. VNS combined with rehabilitation is feasible, with good long-term adherence, and may improve arm function after ischemic stroke.


Seizure ◽  
2006 ◽  
Vol 15 (7) ◽  
pp. 491-503 ◽  
Author(s):  
Andreas V. Alexopoulos ◽  
Prakash Kotagal ◽  
Tobias Loddenkemper ◽  
Jeffrey Hammel ◽  
William E. Bingaman

2009 ◽  
Vol 16 (2) ◽  
pp. 321-324 ◽  
Author(s):  
Konstantin Kostov ◽  
Hrisimir Kostov ◽  
Erik Taubøll

Sign in / Sign up

Export Citation Format

Share Document